Skip to search formSkip to main contentSkip to account menu

Vizamyl

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
In vivo imaging of fibrillar β-amyloid deposits may assist clinical diagnosis of Alzheimer’s disease (AD), aid treatment… 
2015
2015
Medicare’s decision to restrict coverage of florbetapir, a diagnostic agent for Alzheimer’s disease, exemplifies an inconsistent… 
Review
2015
Review
2015
In Alzheimer’s disease (AD), the deposition of β-amyloid (Aβ) is hypothesized to result in a series of secondary… 
2014
2014
The application of microfluidics to the synthesis of Positron Emission Tomography (PET) tracers has been explored for more than a… 
Review
2014
Review
2014
Therapies targeting amyloid-β peptide currently represent approximately 50% of drugs now being developed for Alzheimer’s disease… 
Review
2014
Review
2014
Therapies targeting amyloid-β peptide currently represent approximately 50% of drugs now being developed for Alzheimer's disease… 
2014
2014
2013年10月25日,美国食品药品监督管理局(FDA)批准由GE Healthcare Ltd的分公司Medi—Physics生产的放射性诊断药物[18F]flutemetamol注射液(Vizamyl)在美国上市。 
2013
2013
Physicians in the US who want to see how much amyloid-beta protein has accumulated in the brains of their patients with Alzheimer… 
2013
2013
There has been tremendous excitement regarding biomarkers that provide in vivo information on neurodegenerative diseases. Until…